Ckd Bio Total Liabilities
Ckd Bio total liabilities. Based on the latest financial reports, Ckd Bio (063160) has total liabilities worth ₩173.48 Billion KRW (≈ $117.57 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ckd Bio (063160) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ckd Bio (2008–2025)
Total liabilities of Ckd Bio from 2008 to 2025. This chart illustrates how Ckd Bio's total liabilities have evolved over time, based on quarterly financial data. Explore Ckd Bio (063160) long-term investment share to see how much of total assets are deployed in long-term investments.
Ckd Bio Competitors by Total Liabilities
The table below lists competitors of Ckd Bio ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MeVis Medical Solutions AG
XETRA:M3V
|
Germany | €5.34 Million |
|
Terracom Ltd
AU:TER
|
Australia | AU$161.47 Million |
|
Jerash Holdings US Inc
NASDAQ:JRSH
|
USA | $20.56 Million |
|
Mindax Ltd
AU:MDX
|
Australia | AU$1.90 Million |
|
Frigoglass S.A.I.C.
AT:FRIGO
|
Greece | €16.84 Million |
|
Xander International
TWO:6118
|
Taiwan | NT$2.52 Billion |
|
Corentec Co Ltd
KQ:104540
|
Korea | ₩90.03 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €4.01 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Ckd Bio's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ckd Bio (063160) total assets.
Liquidity & Leverage Metrics
Ckd Bio Total Liabilities Ratios Explained
Ckd Bio total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ckd Bio's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ckd Bio (2008–2025)
The table below shows the annual total liabilities of Ckd Bio from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩172.83 Billion ≈ $117.13 Million |
+12.61% |
| 2024-12-31 | ₩153.48 Billion ≈ $104.01 Million |
-10.12% |
| 2023-12-31 | ₩170.76 Billion ≈ $115.72 Million |
+3.62% |
| 2022-12-31 | ₩164.79 Billion ≈ $111.68 Million |
+20.24% |
| 2021-12-31 | ₩137.05 Billion ≈ $92.88 Million |
+19.47% |
| 2020-12-31 | ₩114.71 Billion ≈ $77.74 Million |
+53.19% |
| 2019-12-31 | ₩74.88 Billion ≈ $50.75 Million |
+103.17% |
| 2018-12-31 | ₩36.86 Billion ≈ $24.98 Million |
-1.55% |
| 2017-12-31 | ₩37.44 Billion ≈ $25.37 Million |
-18.17% |
| 2016-12-31 | ₩45.75 Billion ≈ $31.00 Million |
+5.73% |
| 2015-12-31 | ₩43.27 Billion ≈ $29.32 Million |
+0.10% |
| 2014-12-31 | ₩43.22 Billion ≈ $29.29 Million |
-16.27% |
| 2013-12-31 | ₩51.62 Billion ≈ $34.99 Million |
-15.75% |
| 2012-12-31 | ₩61.28 Billion ≈ $41.53 Million |
-22.72% |
| 2011-12-31 | ₩79.29 Billion ≈ $53.73 Million |
+88.21% |
| 2010-12-31 | ₩42.13 Billion ≈ $28.55 Million |
-10.72% |
| 2009-12-31 | ₩47.18 Billion ≈ $31.98 Million |
+3.25% |
| 2008-12-31 | ₩45.70 Billion ≈ $30.97 Million |
-- |
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more